This document describes the funding and supply arrangements for inclisiran (Leqvio®) as an option in the lipid management pathway. It notes inclisiran is funded centrally by NHS England and that in July 2024 these arrangements will be assessed. The current arrangements have been extended to the end of September 2024 and the position outlined in the document remains as is, and therefore during this time and until notified otherwise there is no impact on new or current patient access to this treatment.